Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The study designed to determine the effect induced by WCK 2349 on the QT interval.
The study will be conducted in two parts: 1) to determine the supratherapeutic dose; and 2)
to assess the safety of high doses of single-dose administration of WCK 2349 on the QT
interval.
Phase:
Phase 1
Details
Lead Sponsor:
Wockhardt
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination